B-cell expansion and lymphomagenesis induced by chronic CD40 signaling is strictly dependent on CD19

Cancer Research

Volumn 74, Issue 16, 2014, Pages 4318-4328

  Hojer, Caroline ^a   Frankenberger, Samantha ^a   Strobl, Lothar J ^a   Feicht, Samantha ^a   Djermanovic, Kristina ^a   Jagdhuber, Franziska ^a   Hom̈ig Hölzel, Cornelia ^a   Ferch, Uta ^b   Ruland, Jürgen ^b   Rajewsky, Klaus ^c   Zimber Strobl, Ursula ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD40 ANTIGEN;

ANIMAL; B LYMPHOCYTE; CELL SURVIVAL; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOMA; MOUSE; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD19; ANTIGENS, CD40; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, TRANSGENIC; PHOSPHORYLATION;

EID: 84905991448     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3274     Document Type: Article

References (31)

1. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1:167-78.
2. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17. (Pubitemid 30046812)
3. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Terry N, Reid PS, et al. A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 2002;16:37-50. (Pubitemid 34143215)
4. Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, et al. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 1998;103:270-5. (Pubitemid 28470831)
5. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44. (Pubitemid 47208626)
6. Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, et al. Constitutive CD40 signaling in B cells selectively activates the non-canonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 2008;205:1317-29. (Pubitemid 351831489)
7. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995;3:39-50.
8. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent Bcell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376:352-5.
9. Otero DC, Anzelon AN, Rickert RC. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol 2003;170:73-83. (Pubitemid 36026125)
10. Brooks SR, Li X, Volanakis EJ, Carter RH. Systematic analysis of the role of CD19 cytoplasmic tyrosines in enhancement of activation in Daudi human B cells: clustering of phospholipase C and Vav and of Grb2 and Sos with different CD19 tyrosines. J Immunol 2000;164:3123-31. (Pubitemid 30148973)
11. Buhl AM, Pleiman CM, Rickert RC, Cambier JC. Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization. J Exp Med 1997;186:1897-910. (Pubitemid 27524599)
12. Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol 1999;162:7088-94. (Pubitemid 29277677)
13. Otero DC, Omori SA, Rickert RC. Cd19-dependent activation of Akt kinase in B-lymphocytes. J Biol Chem 2001;276:1474-8. (Pubitemid 32096580)
14. Tuveson DA, Carter RH, Soltoff SP, Fearon DT. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 1993;260:986-9. (Pubitemid 23209973)
15. Wang Y, Brooks SR, Li X, Anzelon AN, Rickert RC, Carter RH. The physiologic role of CD19 cytoplasmic tyrosines. Immunity 2002;17:501-14. (Pubitemid 35223538)
16. Weng WK, Jarvis L, LeBien TW. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. J Biol Chem 1994;269:32514-21.
17. Anzelon AN, Wu H, Rickert RC. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol 2003;4:287-94. (Pubitemid 36322140)
18. Gardby E, Chen XJ, Lycke NY. Impaired CD40-signalling in CD19-deficient mice selectively affects Th2-dependent isotype switching. Scand J Immunol 2001;53:13-23. (Pubitemid 32113352)
19. Rickert RC, Roes J, Rajewsky K. Blymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res 1997;25:1317-8.
20. Hampel F, Ehrenberg S, Hojer C, Draeseke A, Marschall-Schroter G, Kuhn R, et al. CD19-independent instruction of murine marginal zone B-cell development by constitutive Notch2 signaling. Blood 2011;118:6321-31.
21. Forster I, Rajewsky K. The bulk of the peripheral B-cell pool in mice is stable and not rapidly renewed from the bone marrow. Proc Natl Acad Sci U S A 1990;87:4781-4.
22. Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012;122:2257-66.
23. Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol 2012;189:2318-25.
24. Ishiura N, Nakashima H, Watanabe R, Kuwano Y, Adachi T, Takahashi Y, et al. Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation. Eur J Immunol 2010;40:1192-204.
25. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000;13:47-57.
26. McCaig AM, Cosimo E, Leach MT, Michie AM. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 2011;153:199-211.
27. Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M, et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2011;108:272-7.
28. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009;139:573-86.
29. Gantke T, Sriskantharajah S, Sadowski M, Ley SC. IkappaB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev 2012;246:168-82.
30. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
31. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200-6. (Pubitemid 30108780)